Associate Professor of Medicine, University Alabama
Hematology
Dr. Robert M. Conry, MD
|
|
Give Review
Robert Conry practices Hematology. He attended University of Alabama Medical Center. University of Alabama Medical Center has a rank of 37 in research and a 17 in primary care He over the years received 3 awards: "America's Top Doctors", "America's Top Doctors for Cancer" and "Meaningful Use Stage 1 Certification". Robert M. Conry, MD is a published doctor and has 43 publications published. The lastest was: 'Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen.' Robert Conry is registered with Medicare.
Publications
- A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic Melanoma.
- InDuction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
- Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced Melanoma and low-normal serum lactate dehydroge...
- ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602).
- NonMalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma.
- gp100 peptide vaccine and interleukin-2 in patients with advanced Melanoma.
- Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal Cancer.
- A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic Melanoma.
- Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected Melanoma at risk for relapse.
- Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic Melanoma.
- Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic Melanoma.
- Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in coloRectal carcinoma patients.
- Response of follicular dendritic Cell sarcoma to gemcitabine and docetaxel: report of two cases and literature review.
- Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV Melanoma: final results of a randomised phase III study (EORTC 18032).
- Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced Melanoma: the Oblimersen Melanoma Study Group.
- Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic Malignant melanoma.
- Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent Cellular cytotoxicity.
- Development of a polynucleotide vaccine from Melanoma antigen recognized by T cells-1 and recombinant protein from Melanoma antigen recognized by T cells-1 for melanom...
- InDuction of anti-tumor immunity by intrasplenic administration of a carcinoembryonic antigen DNA vaccine.
- SEREX Analysis for tumor antigen identification in a mouse model of adenocarcinoma.
- Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine.
- Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenoCarcinoma: comparison of intradermal versus subcutaneous administrat...
- Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen.
- Humoral and Cellular immune responses of dogs immunized with a nucleic acid vaccine encoding human carcinoembryonic antigen.
- Effects of a novel purine nucleoside phosphorylase inhibitor, BCX-34, on activation and proliferation of normal human lymphoid Cells.
- Incorporation of beta-globin untranslated regions into a Sindbis virus vector for augmentation of heterologous mRNA expression.
- Immunization with a plasmid expressing pneumococcal surface protein A (PspA) can elicit protection against fatal infection with Streptococcus pneumoniae.
- Selected strategies to augment polynucleotide immunization.
- Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's Lymphoma: effect of an intensive schedule of administration.
- Polynucleotide-mediated immunization therapy of Cancer.
- An animal model to predict the immunogenicity of murine V regions in humans.
- Immune response to a carcinoembryonic antigen polynucleotide vaccine.
- Human immune response to monoclonal antibodies.
- Characterization of a messenger RNA polynucleotide vaccine vector.
- A Sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo.
- A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity.
- Optimization of methods to achieve mRNA-mediated transfection of tumor Cells in vitro and in vivo employing cationic liposome vectors.
- A carcinoembryonic antigen polynucleotide vaccine for human clinical use.
- IntraCellular single-chain antibody directed against erbB2 down-regulates Cell surface erbB2 and exhibits a selective anti-proliferative effect in erbB2 overexpressing...
- Characterization of poliovirus replicons encoding carcinoembryonic antigen.
- Lack of T-Cell immunity in humans with preexisting anti-mouse immunoglobulin reactivity.
- Immunization of colorectal Cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and wit...
Schools
University Of Alabama School Of Medicine
University Al
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Meaningful Use Stage 1 Certification
Education
-
University of Alabama Medical Center -
University of Alabama School of Medicine
Hospital
-
University of Alabama Hospital
Drug Facts
| NPI NUMBER | 1548203235 | |
| NPPES Provider LastName | CONRY | |
| NPPES Provider FirstName | ROBERT | |
| NPPES Provider ZIPCode | 35233 | |
| NPPES Provider State | AL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 875.0 | |
| Distinct Opioid Count | 3.0 | |
| Opioid Claim Count | 69.0 | |
| Percent Opioid Claims | 7.89 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1548203235 |
| Last Name Of The Provider | CONRY |
| First Name Of The Provider | ROBERT |
| View All |
Similar Doctors
|
|
Dr. Daniel J. Allendorf, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jimmie H. Harvey Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shailendra Lakhanpal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William B. Donnellan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cara C. Bondly, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Luz M. Burgos Fuster, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Luigi F. Bertoli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Racquel D. Innis-Shelton, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Lisa C. Larson, MD |
|
|
Dr. Richard D. Lopez, MD |
|
|
Dr. Laurie E. Douglas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary A. Vu, MD |
|
|
Dr. John L. Hartman IV, MD |
|
|
Dr. John R. Nicholson III, MD |
|
|
Dr. John R. Ross, MD |
|
|
Jujjavarap Jujjavarap |
|
|
Ankit Madan, MB BS |